Medical Advocates
Efavirenz (Sustiva/Strocrin)
 
Journal Citations:
Treatment Strategies

Dosage                                HIV/Malaria Coinfection
 Simplification Therapy
 Intensification Therapy
 Treatment Interruption
Switching Therapies
Salvage Therapy
 Hepatic Disease
 Renal Disease
Metabolic Disorders
 HIV/HCV Coinfection
 HIV/TB Coinfection
Efavirenz Adult Treatment Main New/Newsworthy  Home Page      
Last Update:  March 06, 2012
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Dosage
 
 
Efavirenz dose reduction in HIV-infected patients.
Lanzafame M, Bonora S, Lattuada E, Vento S.
HIV Med. 2012 Apr;13(4):252-3. d
 Abstract

Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in
HIV-Associated Tuberculosis: A Randomized Clinical Trial.
 Swaminathan S, Padmapriyadarsini C, Venkatesan P,  et al
Clin Infect Dis. 2011 Oct;53(7):716-24.
 Abstract

A WEEK-IN REVIEW FEATURED REPORT
The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About
 HAART on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study.
 Cooper V, Horne R, Gellaitry G, et al
J Acquir Immune Defic Syndr. 2010 Mar 1;53(3):369-77.
 Abstract

A WEEK-IN REVIEW FEATURED REPORT
The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAART
on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study.
 Cooper V, Horne R, Gellaitry G, et al 
J Acquir Immune Defic Syndr. 2010 Jan 19
 Abstract

A WEEK-IN-REVIEW-FEATURED REPORT
Efavirenz Dose Reduction Is Safe in Patients With High Plasma Concentrations and May
Prevent Efavirenz Discontinuations.
van Luin M, Gras L, Richter C, et al
J Acquir Immune Defic Syndr. 2009 Jul 10.
 Abstract

A WEEK-IN-REVIEW-FEATURED REPORT
Stepped-Dose vs. Full-Dose Efavirenz for HIV Infection and Neuropsychiatric
Adverse Events: A Randomized Trial.
Gutiérrez-Valencia A, López-Cortés LF, et al
 Ann Intern Med. 2009 Jul 6
 Abstract

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome
P450 2B6 *6 and *26.
 Gatanaga H, Hayashida T, Tsuchiya K, et al  
 Clin Infect Dis. 2007 Nov 1;45(9):1230-7.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Outcomes of dosage adjustments used to manage antiretroviral drug interactions.
 Park-Wyllie LY, Levine MA, Holbrook A, et al
Clin Infect Dis. 2007 Oct 1;45(7):933-
Abstract  
Simplification Therapy
 
  Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with
nevirapine, efavirenz or abacavir.
 de Echaguen AO, Arnedo M, Xercavins M, et al
AIDS. 2005 Sep 2;19(13):1385-1391.
Abstract
Intensification Therapy
 
  A WEEK-IN-REVIEW FEATURED REPORT
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected
patients with virological suppression.
Gulick RM, Lalama CM, Ribaudo HJ, et al
AIDS. 2007 Apr 23;21(7):813-823.
Abstract
Treatment Interruption
 
 
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic
resistance after treatment interruption.
 Darwich L, Esteve A, Ruiz L, et al
Antivir Ther. 2008;13(7):945-51.
 Abstract
Switching Therapy
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination
or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
 Bommenel T, Launay O, Meynard JL, et al
J Antimicrob Chemother. 2011 Jun 1
 Abstract

A WEEK-IN REVIEW FEATURED REPORT
Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves
quality of life, treatment satisfaction and adherence with low rates of virological
failure in virologically suppressed patients.
Campo RE, Cohen C, Grimm K, et al
Int J STD AIDS. 2010 Mar;21(3):166-71.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected
patients who developed nevirapine-associated skin rash.
 Kiertiburanakul S, Malathum K, Watcharananan S, et al
 Int J STD AIDS. 2009 Mar;20(3):176-9.
 Abstract

A WEEK IN REVIEW FEATURED REPORT
Switch to Efavirenz (EFV) after Protease-inhibitor (PI) - Failure: Explorative Analysis o
f Outcome by Baseline Viral VS
Tolerability Failure.
 Khaykin P, Postel N, Reeb I, Staszewski S
 Eur J Med Res. 2008 Apr 30;13(4):169-72.
 Abstract
 

Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
 Mehta U, Maartens G.
 Lancet Infect Dis. 2007 Nov;7(11):733-8.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Comparative biological and clinical outcomes after a switch from a virologically unsuccessful
first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing
efavirenz, nevirapine, or abacavir.
 Abgrall S, Yeni PG, Bouchaud O, et al
 Clin Infect Dis. 2007 Jan 1;44(1):120-7.
 Abstract
 
Switch from a first virologically effective protease inhibitor-containing regimen to a
regimen containing efavirenz, nevirapine or abacavir.
 Abgrall S, Yeni PG, Bouchaud O, et al 
AIDS. 2006 Oct 24;20(16):2099-106.
 Abstract
 
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
Fisac C, Fumero E, Crespo M, et al
AIDS. 2005 Jun 10;19(9):917-925
 Abstract

Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
 Saah AJ, Haas DW, DiNubile MJ, et al.
 J Infect Dis 2003 Apr 1;187(7):1157-62
 Abstract
  Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk
groups:a case-control study from the Swiss HIV Cohort,
Hirschel B, Flepp M, Bucher HC, et al .
 AIDS 2002 Feb 15;16(3):381-385
 Abstract
  Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine
or to  efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.
Negredo E, Cruz L, Paredes R, Ruiz L, et al.
 Clin Infect Dis 2002 Feb 15;34(4):504-10
Abstract
  Switch to efavirenz in a protease inhibitor-containing regimen.
Knechten H, Sturner KH, Hohn C, Braun P.
HIV Clin Trials 2001 May-Jun;2(3):200-4
 Abstract
Salvage Therapy
 
 
Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and
efavirenz salvage regimen.
 Vallejo A, Olivera M, Rubio A, et al.
Antiviral Res. 2004 Feb;61(2):129-32
 Abstract

Modulation of Human Immunodeficiency Virus (HIV)-Specific Immune Response by Using Efavirenz,
Nelfinavir, and Stavudine in a Rescue Therapy Regimen for HIV-Infected, Drug-Experienced Patients.
Trabattoni D, Lo Caputo S, Biasin M, et al.
Clin Diagn Lab Immunol 2002 Sep;9(5):1114-8
 Abstract

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after
nevirapine failure.
 Antinori A, Zaccarelli M, Cingolani A, et al.
AIDS Res Hum Retroviruses 2002 Aug 10;18(12):835-8
 Abstract

  
Hepatic Disease
 
  Efavirenz-therapy in HIV-patients with Underlying Liver Disease: Importance of Continuous TDM
of EFV.
Katsounas A, Frank A, Klinker H, Langmann P.
 Eur J Med Res. 2007 Aug 16;12(8):331-6
 Abstract
Renal Disease
 
  Experience with efavirenz in end-stage renal disease.
Prime KP, Woolfson RG, Pakianathan MR
 Int J STD AIDS. 2003 Jul;14(7):497-8.
 Abstract
Metabolic Disorders
 
 
Impact of Efavirenz on Intestinal Metabolism and Transport: Insights From an Interaction Study
With Ezetimibe in Healthy Volunteers.
Oswald S, Meyer Zu Schwabedissen HE, et al
Clin Pharmacol Ther. 2012 Feb 1.
 Abstract

The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active
antiretroviral therapy.
 Pérez-Molina JA, Domingo P, Martínez E, Moreno S.
J Antimicrob Chemother. 2008 May 14
 Abstract

Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in
HIV-infected patients.
 Pereira SA, Branco T, Corte-Real RM,
 Br J Clin Pharmacol. 2006 May;61(5):601-4
 Abstract

Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the
management of dyslipidaemia.
 Calza L, Manfredi R, Colangeli V, et al 
AIDS. 2005 Jul 1;19(10):1051-8. R
 Abstract
HIV/HCV Coinfection
 
 
Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.
 Pineda JA, Neukam K, Mallolas J,  et al
J Infect. 2011 Nov 25.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
 Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis
B or C.
 Meynard JL, Lacombe K, Poirier JM, et al 
J Antimicrob Chemother. 2009 Jan 23.
 Abstract

Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV-
Coinfected Patients.
 Quereda C, Corral I, Moreno A, Pérez-Elías MJ,
 J Acquir Immune Defic Syndr. 2008 Jul 23.
Abstract
HIV/Tuberculosis Coinfection
 
 
A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients.
 Yimer G, Ueda N, Habtewold A, Amogne W,  et al
PLoS One. 2011;6(12):e27810
 Paper

The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
 Gengiah TN, Holford NH, Botha JH, et al
Eur J Clin Pharmacol. 2011 Nov 23.
 Abstract

Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis:
A Randomized Clinical Trial.
 Swaminathan S, Padmapriyadarsini C, Venkatesan P,  et al
Clin Infect Dis. 2011 Oct;53(7):716-24.
 Abstract

Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
 Orrell C, Cohen K, Conradie F, et al
Antivir Ther. 2011;16(4):527-34.
 Abstract

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with
CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.
 Kwara A, Lartey M, Sagoe KW, Court MH.
AIDS. 2010 Dec 9
 Abstract

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine
levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.
 Uttayamakul S, Likanonsakul S, Manosuthi W,  et al
 AIDS Res Ther. 2010 Mar 26;7(1):8
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Body Weight Cutoff for Daily Dosage of Efavirenz and 60-week Efficacy of Efavirenz-
based Regimen in Co-infected HIV and Tuberculosis Patients Receiving Rifampin.
Manosuthi W, Sungkanuparph S, Tantanathip P,  et al
Antimicrob Agents Chemother. 2009 Aug 10
 Abstract

Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB/HIV Co-infected Patients:
Pharmacogenetic Effect of CYP2B6 Variation.
 Kwara A, Lartey M, Sagoe KW, et al  
J Clin Pharmacol. 2008 Sep;48(9):1032-40.
 Abstract
 
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels
but excellent clinical outcomes in patients treated for tuberculosis and HIV.
 Friedland G, Khoo S, Jack C, Lalloo U.  
J Antimicrob Chemother. 2006 Oct 10;
Abstract

Efavirenz trough levels are not associated with virological failure throughout therapy
with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, et al
J Antimicrob Chemother. 2006 Sep 6;
 Abstract
HIV/Malaria Coinfection
 
  Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir
or atazanavir/ritonavir.
 van Luin M, Van der Ende ME, Richter C,  et al 
AIDS. 2010 May 15;24(8):1223-6.
 Abstract

Efavirenz Adult Treatment Main New/Newsworthy  Home Page      

Efavirenz Journal Citations: Adult/Adolescent Treatment